Do you want to read an article? Please log in or register.
Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial
Breast Cancer
Related content
Breast Cancer
Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial
JAMA Oncol
Fasching PA, Stroyakovskiy D, Yardley DA, Huang CS, Crown J, Bardia A, Chia S, Im SA, Martin M, Xu B, Loi S, Barrios C, Untch M, Moroose R, Visco F, Hortobagyi GN, Slamon DJ, Fresco R, Zarate JP, Li Z, Waters S, Hurvitz SA
doi: 10.1001/jamaoncol.2025.3700
Breast Cancer
Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1
J Clin Oncol
Offersen BV, Alsner J, Høgsbjerg K, Nielsen HM, Maae E, Nielsen MH, Mjaaland I, Maraldo MV, Kirkove C, Lörincz T, Al-Rawi S, Blix ES, Schreiber A, Krause M, Kasti UM, Matthiessen LW, Kronborg C, Tramm T, Jensen MB, Overgaard J, DBCG RT Committee
doi: 10.1200/JCO-25-02705
Breast Cancer
Chemotherapy-Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline-Free Regimen With Docetaxel, Cyclophosphamide-Results From a Randomized Clinical Trial
Int J Cancer
Hörner M, Schäffler H, Häberle L, Goossens C, Pfister K, Leinert E, Veselinovic K, Brucker SY, Köhler U, Heinrich G, Schneeweiss A, Beckmann MW, Fasching PA, Janni W, Rack B, Heublein S, Ziegler P
doi: 10.1002/ijc.70528
Breast Cancer
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial
Ann Oncol
Harbeck N, Modi S, Pusztai L, Ohno S, Wu J, Kim SB, Yoshida A, Fabi A, Cao X, Joseph R, Li R, Żurawski B, Escrivá-de-Romaní S, Meneguetti R, Supavavej A, Chen SC, Liu Z, Kelly C, Curigliano G, Symmans WF, Gufran M, Ke J, Konpa A, Herbolsheimer P, Boileau JF, DESTINY-Breast11 Trial Investigators
doi: 10.1016/j.annonc.2025.10.019
Breast Cancer
Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial
Ann Oncol
Garber JE, Cameron D, Campbell C, Yothers G, Taboada M, El-Abed S, Rastogi P, McConnell R, Correa A, Delaloge S, Liu WT, Sharma P, Bergh J, Janni W, Balmaña J, Loman N, Španić T, Friedman S, Freeman T, Armstrong A, Korde L, Im S, Sagara Y, Viale G, Bliss J, Gianni L, Jóhannsson Ó, Zoppoli G, De Dueñas EM, Marmé F, Fein L, Arnedos M, Ford J, Schmutzler R, Loibl S, Linderholm B, Lakhani SR, Gnant M, Gelmon K, Domchek SM, Senkus E, Eisen A, Jager A, Piccart M, Phillips KA, Traina T, Stickeler E, Singer CF, Shao Z, Liu X, Tipping H, Aktan G, Martinez M, Canon JL, Takahashi M, Yasojima H, Middleton K, Pristauz-Telsnigg G, Pfeiler G, Virani S, Valdes-Albini F, Wolmark N, Mesa ID, Paterson V, Gelber RD, Geyer CE Jr, Tutt ANJ
doi: 10.1016/j.annonc.2026.08.002
ESMO 2025
Breast Cancer
DESTINY-Breast11: Neoadjuvant T-DXd plus THP significantly improves pCR in high-risk HER2-positive early breast cancer
Breast Cancer
Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial
J Clin Oncol
Gupta S, Nair N, Hawaldar RW, Joshi S, Gulia S, Shet T, Sarin R, Parmar V, Desai S, Ghosh J, Wadasadawala T, Vanmali V, Panhale T, Parab P, Patil A, Chitkara G, Rath S, Bajpai J, Pathak R, Popat P, Thakur M, Badwe RA
doi: 10.1200/JCO-25-01023
RECOMMENDED
Breast Cancer
Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial
★ 3
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
J Clin Oncol
Chen X, Huang J, Shi H, Zhu J, Wu W, Ye G, He Q, Shi Y, Zhang A, Xie X, Wang X, Chen X, Wu W, Wu J, Li Z, Li Z, Dai Y, Ren W, Shao Q, Chen Y, Zeng Y, Zhang F, Dong S, Pegram MD, Shen K
doi: 10.1200/JCO-25-02412
Breast Cancer
Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial
JAMA Oncol
Tarantino P, Li T, Ogayo ER, Rahman T, DiLullo MK, Patel A, El-Refai S, Abbott C, Li B, Boyle SM, Chen RO, Desai NV, Spring LM, Tung NM, Sinclair N, Faggen M, Constantine M, King TA, Krop IE, Tayob N, Mittendorf EA, Tolaney SM, Winer EP, Parsons HA, Waks AG
doi: 10.1001/jamaoncol.2026.2023